Background: Laron syndrome is caused by a mutation in the growth hormone (GH) receptor and manifests as insulin-like growth factor-I (IGF-I) deficiency, severe short stature, and early hypoglycemia. We report a case with postprandial hyperglycemia, an abnormality not reported previously. Postprandial hyperglycemia was due to chronic IGF-I deficiency, and was reversed by IGF-I replacement therapy. Methods: A Moroccan girl referred for short stature at 7 years and 8 months of age had dwarfism [height, 78 cm (–9 SDs); weight, 10 kg (–4 SDs)], hypoglycemia, and truncal obesity. Her serum IGF-I level was very low, and her baseline serum GH level was elevated to 47 mIU/l. Molecular analysis showed a homozygous mutation in the GH receptor gene. Results: Continuous glucose monitoring before treatment showed asymptomatic hypoglycemia with postprandial hyperglycemia (2.5 g/l, 13.75 mmol/l). Treatment with recombinant human IGF-I (mecasermin, Increlex®) was started. The blood glucose profile improved with 0.04 µg/kg/day and returned to normal with 0.12 µg/kg/day. Conclusion: Postprandial hyperglycemia is a metabolic consequence of chronic IGF-I deficiency. The beneficial effect of IGF-I replacement therapy may be ascribable to improved postprandial transfer of glucose.

1.
Laron Z, Pertzelan A, Mannheimer S: Genetic pituitary dwarfism with high serum concentration of growth hormone – a new inborn error of metabolism? Isr J Med Sci 1966;2:152–155.
2.
Laron Z, Kopchick J: Laron Syndrome – From Man to Mouse. Springer, Berlin, 2010.
3.
Edouard T, Raynal P, Yart A, et al: Nouveaux mécanismes moléculaires impliqués dans l’insensibilité à l’hormone de croissance. Arch Pediatr 2008;15:179–188.
4.
Kopchick JJ, Andry JM: Growth hormone (GH), GH receptor, and signal transduction. Mol Genet Metab 2000;71:293–314.
5.
Lupu F, Terwilliger JD, Lee K, Segre GV, et al: Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001;229:141–162.
6.
Brooks AJ, Waters MJ: The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol 2010;6:515–525.
7.
Berg MA, Argente J, Chernausek S, et al: Diverse growth hormone receptor gene mutations in Laron syndrome. Am J Hum Genet 1993;52:998–1005.
8.
Chatelain P, Carel JC, Nicolino M, et al: Les résultats des traitements par l’IGF1. Arch Pediatr 1996;3(suppl I):144s–147s.
9.
Fintini D, Brufan C, Cappa M: Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-I deficiency. Ther Clin Risk Manag 2009;5:553–559.
10.
Klinger B, Laron Z: Three year IGF- I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab 1995;8:149–158.
11.
Laron Z: Insulin-like growth factor-I treatment of children with Laron syndrome. Pediatr Endocrinol Rev 2008;5:766–771.
12.
Backeljauw P, Bang P, Clayton PE, Geffner M, Woods KA: Diagnosis and management of primary insulin-like growth factor-I deficiency: current perspectives and clinical update. Pediatr Endocrinol Rev 2010;7(suppl 1):154–171.
13.
Ranke MB, Savage MO, Chatelain PG, et al: Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999;51:128–134.
14.
Guevara-Aguirre J, Rosenbloom AL, Vasconez O, et al: Two year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab 1997;82:629–633.
15.
Blethen SL, Compton P, Lippe BM, Rosenfeld RG, August GP, Johanson A: Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency. J Clin Endocrinol Metab 1993;76:574–579.
16.
Bakker B, Frane J, Anhalt H, Lippe B, Rosenfeld RG: Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab 2008;93:352–357.
17.
Le Roith D, Scavo L, Bulter A: What is the role of circulating IGF-I? Trends Endocrinol Metab 2001;12:48–52.
18.
Rosenbloom AL: The role of recombinant insulin-like growth factor I in the treatment of the short child. Curr Opin Pediatr 2007;19:458–464.
19.
Camacho-Hübner C, Rose S, Preece MA, et al: Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. J Clin Endocrinol Metab 2006;91:1246–1253.
20.
Chernausek SD, Backeljauw PF, Frane J, et al: Long-term treatment with recombinant insulin-like growth factor(IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007;92:902–910.
21.
Laron Z: Consequences of not treating children with Laron syndrome. J Pediatr Endocrinol Metab 2001;14:1243–1248.
22.
Laron Z, Avitzur Y, Klinger B: Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. Metabolism 1995;44(suppl 4):113–118.
23.
Laron Z: Hypoglycemia due to hormone deficiencies. J Pediatr Endocrinol Metab 1998;11:117–120.
24.
Froesch ER, Hussain M: The metabolic effects of the insulin-like factor I with special reference to diabetes. Acta Paediatr 1994;399(suppl):41–49.
25.
Walker JL, Ginalska-Malinowska M, Romer TE, et al: Effects of the infusion of insulin- like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism). N Engl Med 1991;324:1483–1488.
26.
Moxley RT, Arner P, Moss A, et al: Acute effects of insulin- like growth factor I and insulin on glucose metabolism in vivo. Am J Physiol 1990;259:561–567.
27.
Berryman DE, List EO, Kohn DT, et al: Effect of growth hormone on susceptibility to diet-induced obesity. Endocrinology 2006;147:2801–2808.
28.
Guler H-P, Zapf JZ, Froesch R: Short- term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl Med 1987;317:137–140.
29.
Ekstrom K, Carlsson-Skwirut C, Ritzen EM, et al: Insulin-like growth factor-I and insulin-like growth factor binding protein-3 co-treatment versus insulin like growth factor- I alone in two brothers with growth hormone insensitivity syndrome: effects on insulin sensitivity, body composition and linear growth. Horm Res Paediatr 2011;76:355–366.
30.
Dimitriadis G, Parry-Billings M, Dunger D, et al: Effects of in-vivo administration of insulin-like growth factor-I on the rate of glucose utilization in the soleus muscle of the rat. J Endocrinol 1992;133:37–43.
31.
Zapf J, Hauri C, Waldvogel M, et al: Acute metabolic effects and half-lives intravenously administered insulin like growth factors I and II in normal and hypophysectomized rats. J Clin Invest 1986;77:1768–1775.
32.
Laron Z, Klingler B, Silbergeld A, et al: Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH. Acta Endocrinol 1990;123:378–382.
33.
Van Schrarendijk CR, Heylen L, Van den Brande JL, et al: Direct effect of insulin and insulin-like growth factor I on the secretory activity of rat pancreatic beta cell. Diabetologia 1990;33:649–653.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.